76 related articles for article (PubMed ID: 8646555)
1. Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region.
Caputo A; Grossi MP; Bozzini R; Rossi C; Betti M; Marconi PC; Barbanti-Brodano G; Balboni PG
Gene Ther; 1996 Mar; 3(3):235-45. PubMed ID: 8646555
[TBL] [Abstract][Full Text] [Related]
2. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication.
Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG
Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients.
Rossi C; Balboni PG; Betti M; Marconi PC; Bozzini R; Grossi MP; Barbanti-Brodano G; Caputo A
Gene Ther; 1997 Nov; 4(11):1261-9. PubMed ID: 9425451
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant.
Balboni PG; Bozzini R; Zucchini S; Marconi PC; Grossi MP; Caputo A; Manservigi R; Barbanti-Brodano G
J Med Virol; 1993 Dec; 41(4):289-95. PubMed ID: 8106862
[TBL] [Abstract][Full Text] [Related]
5. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
[TBL] [Abstract][Full Text] [Related]
6. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells.
Liu J; Woffendin C; Yang ZY; Nabel GJ
Gene Ther; 1994 Jan; 1(1):32-7. PubMed ID: 7584057
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer.
Li Y; Starr SE; Lisziewicz J; Ho WZ
Gene Ther; 2000 Feb; 7(4):321-8. PubMed ID: 10694813
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
Kashanchi F; Sadaie MR; Brady JN
Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
[TBL] [Abstract][Full Text] [Related]
9. Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag.
Lori F; Lisziewicz J; Smythe J; Cara A; Bunnag TA; Curiel D; Gallo RC
Gene Ther; 1994 Jan; 1(1):27-31. PubMed ID: 7584056
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B
Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770
[TBL] [Abstract][Full Text] [Related]
11. Rates of shutdown of HIV-1 into latency: roles of the LTR and tat/rev/vpu gene region.
Song SK; Li H; Cloyd MW
Virology; 1996 Nov; 225(2):377-86. PubMed ID: 8918924
[TBL] [Abstract][Full Text] [Related]
12. Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication.
Verhoef K; Koper M; Berkhout B
Virology; 1997 Oct; 237(2):228-36. PubMed ID: 9356335
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
14. Gradual shutdown of virus production resulting in latency is the norm during the chronic phase of human immunodeficiency virus replication and differential rates and mechanisms of shutdown are determined by viral sequences.
Li XD; Moore B; Cloyd MW
Virology; 1996 Nov; 225(1):196-212. PubMed ID: 8918547
[TBL] [Abstract][Full Text] [Related]
15. Requirement of an additional Sam68 domain for inhibition of human immunodeficiency virus type 1 replication by Sam68 dominant negative mutants lacking the nuclear localization signal.
Zhang J; Liu Y; Henao J; Rugeles MT; Li J; Chen T; He JJ
Gene; 2005 Dec; 363():67-76. PubMed ID: 16236470
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells.
Mahlknecht U; Dichamp I; Varin A; Van Lint C; Herbein G
J Leukoc Biol; 2008 Mar; 83(3):718-27. PubMed ID: 18070983
[TBL] [Abstract][Full Text] [Related]
17. H. saimiri tyrosine-kinase interacting protein inhibits Tat function: a prototypic strategy for restricting HIV-1-induced cytopathic effects in immune cells.
Raymond AD; Hasham M; Tsygankov AY; Henderson EE
Virology; 2006 Sep; 352(2):253-67. PubMed ID: 16780912
[TBL] [Abstract][Full Text] [Related]
18. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication.
Accolla RS; Mazza S; De Lerma Barbaro A; De Maria A; Tosi G
Eur J Immunol; 2002 Oct; 32(10):2783-91. PubMed ID: 12355430
[TBL] [Abstract][Full Text] [Related]
19. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
